

29th March, 2018

Ref.: ID/AS/Outcome

The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001.

The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051.

Dear Sir,

Sub: Outcome of the Board Meeting in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In terms of Regulation 30 read with Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. CIR/CFD/CMD/4/2015 as amended from time to time, we hereby inform you that the Board of Directors of the Company at its meeting held on 28th March, 2018 have taken the following decisions:

1. Re-appointed Mr.Arun Kumar Kothari (DIN-00051900) as Wholetime Director and designated him as "Executive Chairman" of the Company with effect from 1st April, 2018 subject to approval by the members of the Company in the next Annual General Meeting. The required details are annexed herewith as Annexure A.
2. Appointed Dr.Tarinder Singh Parmar (DIN-05118311), currently functioning as Chief Executive Officer of the Company, as an Additional Director (Executive) and designated him as "Managing Director & CEO" of the Company with effect from 1st April, 2018 subject to approval by the members of the Company in the next Annual General Meeting. The required details are annexed herewith as Annexure B.
3. Approved the retirement of Mr. H. P. Kabra, Executive Director of the Company on expiry of his tenure on 31st March, 2018.

The Board Meeting commenced at 4:30 p.m. and concluded at 6:25 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,
For Albert David Limited




Indrajit Dhar
Associate Vice President (Accounts &
Taxation)-cum-Company Secretary

Encl.: As above

ANNEXURE A

Details required under Regulation 30 read with Schedule III Part A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 for (re)appointment of Mr. Arun Kumar Kothari as Wholetime Director designated as Executive Chairman of the Company.

Sl. No.	Details of events that need to be provided	Information of such event(s)
1.	Reason for change:	<u>(Re)appointment</u> Mr. A. K. Kothari (DIN-00051900) currently functioning as Chairman & Managing Director whose term will expire on 31 st March, 2018 has been (re)appointed as Wholetime Director designated as "Executive Chairman" of the Company with effect from 1 st April, 2018.
2.	a) Date of appointment: b) Term of appointment:	1 st April, 2018. Three years with effect from 1 st April, 2018 to hold office upto close of business hours on 31 st March, 2021 subject to the approval of shareholders in the next Annual General Meeting.
3.	Brief profile of Mr. Arun Kumar Kothari:	Mr. A. K. Kothari aged about 65 years is a Commerce graduate and an well-known industrialist having vast experience in the businesses of Pharmaceuticals, Tea, Chemicals, Engineering & Textile industry. He is associated with the Company as Director since 1988.
4.	Relationship between Directors:	Mr. A. K. Kothari is related to Smt. P. D. Kothari, Director of the Company, as spouse.



ANNEXURE B

Details required under Regulation 30 read with Schedule III Part A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 for appointment of Dr. Tarminder Singh Parmar as Managing Director & CEO of the Company.

Sl. No.	Details of events that need to be provided	Information of such event(s)
1.	Reason for change:	<u>Appointment</u> Dr. T. S. Parmar (DIN-00518311) currently functioning as the Chief Executive Officer has been appointed as Additional Director (Executive) and designated as the "Managing Director & CEO" of the Company with effect from 1 st April, 2018.
2.	a) Date of appointment: b) Term of appointment:	1 st April, 2018. Five years with effect from 1 st April, 2018 to hold office upto close of business hours on 31 st March, 2023 subject to the approval of shareholders in the next Annual General Meeting.
3.	Brief profile of Dr. Tarminder Singh Parmar:	Dr. T. S. Parmar (DIN-05118311) is B.Sc. & M.B.A. and has nearly 30 years of experience in several reputed pharmaceutical companies in senior positions. He has been functioning as Chief Executive Officer of the Company from 24th January, 2017.
4.	Relationship between Directors:	Dr. T. S. Parmar is not related to any of the Directors of the Company.

